IDEXX Laboratories, Inc. (IDXX): Price and Financial Metrics

IDEXX Laboratories, Inc. (IDXX)

Today's Latest Price: $493.50 USD

1.54 (-0.31%)

Updated Jan 21 12:34pm

Add IDXX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 186 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

IDXX Stock Summary

  • With a market capitalization of $42,226,859,031, Idexx Laboratories Inc has a greater market value than 94.49% of US stocks.
  • Idexx Laboratories Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 93.68% of US listed stocks.
  • With a one year PEG ratio of 646.5, Idexx Laboratories Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 94% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Idexx Laboratories Inc, a group of peers worth examining would be BAX, A, ALGN, EBAY, and CSGP.
  • Visit IDXX's SEC page to see the company's official filings. To visit the company's web site, go to

IDXX Stock Price Chart Interactive Chart >

Price chart for IDXX

IDXX Price/Volume Stats

Current price $493.50 52-week high $516.86
Prev. close $495.04 52-week low $168.65
Day low $487.48 Volume 72,024
Day high $496.45 Avg. volume 369,792
50-day MA $473.25 Dividend yield N/A
200-day MA $380.07 Market Cap 42.10B

IDEXX Laboratories, Inc. (IDXX) Company Bio

IDEXX Laboratories develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. The company was founded in 1983 and is based in Westbrook, Maine.

IDXX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$493.50$123.52 -75%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Idexx Laboratories Inc. To summarize, we found that Idexx Laboratories Inc ranked in the 22th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Idexx Laboratories Inc, consider:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 98. Notably, its equity weight is greater than 81.49% of US equities in the Healthcare sector yielding a positive free cash flow.
  • The business' balance sheet suggests that 2% of the company's capital is sourced from debt; this is greater than only 10.9% of the free cash flow producing stocks we're observing.
  • IDXX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 48.48% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

BSX, HZNP, MDT, NUVA, and PRGO can be thought of as valuation peers to IDXX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

IDXX Latest News Stream

Event/Time News Detail
Loading, please wait...

IDXX Latest Social Stream

Loading social stream, please wait...

View Full IDXX Social Stream

Latest IDXX News From Around the Web

Below are the latest news stories about Idexx Laboratories Inc that investors may wish to consider to help them evaluate IDXX as an investment opportunity.

Why You Should Retain Pacific Biosciences (PACB) Stock Now

Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects.

Yahoo | January 20, 2021

ESG Stocks to Gather Speed Under Biden's Leadership: 5 Picks

Biden's administration plans to address climate change and take ESG initiatives. This call for investing in Shopify (SHOP), Magna International (MGA), IDEXX Lab (IDXX), Facebook (FB) and PayPal (PYPL).

Yahoo | January 20, 2021

Omnicell (OMCL) Reports Encouraging 2020 Preliminary Results

Per the preliminary announcement, Omnicell (OMCL) projects 2020 total revenues to surpass its previous guidance.

Yahoo | January 19, 2021

Intersect ENT's (XENT) Q4 Preliminary Revenues Disappointing

Per the preliminary announcement, Intersect ENT (XENT) projects Q4 revenues to decline from the year-ago quarter's reported figure.

Yahoo | January 18, 2021

Masimo (MASI) Reports Encouraging 2020 Preliminary Results

Per the preliminary announcement, Masimo (MASI) projects 2020 product revenues to improve.

Yahoo | January 15, 2021

Read More 'IDXX' Stories Here

IDXX Price Returns

1-mo -1.13%
3-mo 14.86%
6-mo 37.38%
1-year 71.58%
3-year 172.73%
5-year 643.67%
YTD -1.27%
2020 91.43%
2019 40.38%
2018 18.95%
2017 33.35%
2016 60.82%

Continue Researching IDXX

Here are a few links from around the web to help you further your research on Idexx Laboratories Inc's stock as an investment opportunity:

Idexx Laboratories Inc (IDXX) Stock Price | Nasdaq
Idexx Laboratories Inc (IDXX) Stock Quote, History and News - Yahoo Finance
Idexx Laboratories Inc (IDXX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8894 seconds.